Biotin supplementation causes erroneous elevations of results in some commercial serum 25-hydroxyvitamin d (25ohd) assays

Publication date: Available online 19 February 2020Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): GD Carter, J Berry, E Cavalier, R Durazo-Arvizu, E Gunter, G Jones, J Jones, K Phinney, CT Sempos, PJ Twomey, EL WilliamsAbstractThe Vitamin D External Quality Assessment Scheme (DEQAS) distributes serum samples globally, on a quarterly basis, to assess participants’ performance of specific methods for 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25-(OH)2D). DEQAS occasionally circulates samples containing high levels of substances found in certain clinical situations e.g. 25-OH-D2, 24,25-(OH)2D3, hypertriglyceridemia. The increased availability and use of health supplements containing biotin has led to case reports of assay interference in methods utilizing a biotin-streptavidin detection system. In October 2018, DEQAS included a serum sample (545) containing exogenous biotin (concentration =586 μg/L) which was analyzed by a total of 683 laboratories using 35 different methods. The same serum sample (544) without exogenous biotin was also included in the 5-sample set. All methods (760 laboratories) performed satisfactorily on sample 544 giving an All-Laboratory Trimmed Mean = 50.2 ± 6.5 nmol/L (±SD, CV = 12.9%). The target value for this sample 544 (& 555) was 47.4 nmol/L as determined by Centers for Disease Control and Prevention (CDC) Atlanta, Georgia using their LC-MS/MS reference method. In contrast, #545 cont...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research